C
Chao Jung Tsao
Researcher at National Cheng Kung University
Publications - 30
Citations - 5873
Chao Jung Tsao is an academic researcher from National Cheng Kung University. The author has contributed to research in topics: Cancer & Nasopharyngeal carcinoma. The author has an hindex of 14, co-authored 27 publications receiving 5134 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
Ann-Lii Cheng,Chao A. Hsiung,Ih-Jen Su,Pei-Jer Chen,Pei-Jer Chen,Ming Chih Chang,Chao Jung Tsao,Woei Yao Kao,Wu Ching Uen,Chih-Hung Hsu,Hwei Fan Tien,Tsu Yi Chao,Li-Tzong Chen,Jacqueline Whang-Peng +13 more
TL;DR: In conclusion, steroid‐free chemotherapy decreases the incidence and severity of HBV reactivation in HBsAg‐positive lymphoma patients, however, further research is needed to evaluate whether steroid-free chemotherapy may confer a less satisfactory control of lymphoma.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
Ann-Lii Cheng,Zhongzhen Guan,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Tsai Sheng Yang,Won Young Tak,Hongming Pan,Shiying Yu,Jianming Xu,Fang Fang,Jessie Zou,Giuseppe Lentini,D. Voliotis,Yoon-Koo Kang +15 more
TL;DR: Experimental analyses suggest that sorafenib is effective for patients from the AP region with advanced HCC, irrespective of baseline status, and the efficacy and safety profiles in the subpopulations described were comparable with those in the overall study population.
Journal ArticleDOI
Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy
TL;DR: Preemptive use of α-interferon or lamivudine in HBsAg-positive lymphoma patients undergoing chemotherapy may be a promising approach to prevent HBV reactivation that carries a risk of delayed treatment or even fatal outcome.
Journal ArticleDOI
Bone marrow that is positive for Epstein-Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type.
Wen Tsung Huang,Kun Chao Chang,Guan Cheng Huang,Jenn Ren Hsiao,Helen H.W. Chen,Shin Sung Chuang,Tsai Yun Chen,Wu Chou Su,Chao Jung Tsao +8 more
TL;DR: The use of EBV-encoded RNA-1 in situ hybridization (EBER-1 ISH) to detect occult micrometastasis in the bone marrow of patients with nasal NK/T-cell lymphoma is suggested to carry a poor prognosis.